Similar Papers

Paper Title
Journal
Date
Author
1275P - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)
B.C Cho ... M.L Johnson
Annals of Oncology | VOL. 30
B.C Cho, et. al.B.C Cho ... M.L Johnson
01 Oct 2019
1196P - Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
...
Annals of Oncology | VOL. 30
, et. al. ...
01 Oct 2019
LBA55 - Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy
S.T Tagawa ... Y Loriot
Annals of Oncology | VOL. 30
S.T Tagawa, et. al.S.T Tagawa ... Y Loriot
01 Oct 2019
1590TiP - Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
...
Annals of Oncology | VOL. 30
, et. al. ...
01 Oct 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
276MO Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: A retrospective cohort study
C-T Wu ... L-N Chien
Annals of Oncology | VOL. 35
C-T Wu, et. al.C-T Wu ... L-N Chien
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.